Who Paid My Doc
Samuel Mehr
Nuclear Medicine Omaha, NE Medical Doctor
NPI 1497781801 CMS profile 690793
17201 Wright St Ste 200, Ste 200, Omaha, NE 68130
General payments
$37,140
Research payments
$8,750
Ownership & investment interest
$0
Research they led as principal investigator
$1,254,184
Through program year 2025, Samuel Mehr of Omaha, NE is reported in the CMS Open Payments database as having received $37,140 across 58 general payments and $8,750 in research payments paid to them. Separately, studies naming them as principal investigator received $1,254,184 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 94th percentile of Nuclear Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $2,763 | 4 | |
| 2024 | General | $1,626 | 7 | |
| 2023 | General | $608 | 4 | |
| 2022 | General | $68 | 5 | |
| 2021 | General | $94 | 4 | |
| 2021 | Research | $8,750 | 1 | |
| 2020 | General | $7,332 | 9 | |
| 2019 | General | $24,649 | 25 |
Beside peers
- Samuel Mehr
- Nuclear Medicine median
- Middle half of Nuclear Medicine
- National median
In program year 2025, general payments to Samuel Mehr were reported at $2,763. Among 197 Nuclear Medicine profiles paid that year, the median was $146 and the middle half received between $40 and $372.
Show as a table
| Year | Samuel Mehr | Nuclear Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $24,649 | $125 | $54–$531 | $163 |
| 2020 | $7,332 | $99 | $34–$2,125 | $114 |
| 2021 | $94 | $96 | $22–$874 | $132 |
| 2022 | $68 | $102 | $38–$240 | $149 |
| 2023 | $608 | $123 | $51–$257 | $160 |
| 2024 | $1,626 | $121 | $51–$390 | $164 |
| 2025 | $2,763 | $146 | $40–$372 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 73 billing codesPaid by Medicare
$2,776,322
Medicare patients
712
Services billed
63,759
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Cancer | 64% | |
| Arthritis | 53% | |
| Chronic kidney disease | 32% | |
| Ischemic heart disease | 29% | |
| Diabetes | 25% | |
| COPD | 24% | |
| Atrial fibrillation | 23% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 | Office | 345 | 48,036 | $4,880 |
| Injection, glucagon hydrochloride, per 1 mg J1610 | Office | 22 | 26 | $3,736 |
| Injection, furosemide, up to 20 mg J1940 | Office | 252 | 448 | $173 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
3 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| Xofigo |
|
$1,371 | — | — |
| JAKAFI |
|
$14 | — | — |
| Padcev |
|
$14 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
Records
59 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Nuclear Medicine in Nebraska
Practitioners in the same specialty and state, ranked by reported value.
All Nuclear Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Nebraska
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.